drugset / Trial / NCT04967092

Modified Xiao-Feng Powder for Chronic Urticaria

NCT04967092

Phase 2 Unknown 58 enrolled Prof. Lin Zhixiu
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Urticaria is a common skin disorder and 15-25% of people experience at least one attack of urticaria during their lifetime. Urticaria can be divided into acute urticaria (AU) and chronic urticaria (CU). CU is more common in adults, and affects women more frequently than men. According to Chinese medicine (CM) theory, CU is known as Yin Zhen. Nowadays, CM is widely used for managing CU in Hong Kong and mainland. Among different Chinese herbal formulae for urticaria, Xiao-Feng Powder (XFP), also known as Wind-Dispersing Powder, is one of the most frequently used Chinese herbal formulae for CU. This study used modified Xiao-Feng Powder (mXFP) to evaluate the effectiveness and safety of mXFP in treating CU. Hence, a double-blind, randomised, placebo-controlled clinical trial design with strong scientific rigor will be employed in this study, and it would be able to provide robust clinical evidence on the efficacy and safety of mXFP for CU.

Timeline

Start
2021-08-15
Primary completion
2023-03-31
Completion
2023-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Modified Xiao-Feng Powder Traditional medicine (herbal / TCM)
Comparator Bilastine Small molecule 20 mg

Indications